Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Applications of anthocyanin and regulation for CHOP gene in preventing and treating atherosclerosis

A technology of atherosclerosis and anthocyanins, applied in the field of medicine, can solve the problems of less depth, inability to antagonize atherosclerosis, and less data, so as to enhance cell proliferation ability, reduce endoplasmic reticulum stress response, and improve The effect of damage

Inactive Publication Date: 2008-12-17
WUHAN UNIV
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, some studies have also found that feeding hereditary hyperlipidemia rabbits with anthocyanins derived from black currant juice found that anthocyanins have no effect on blood lipid metabolism in hyperlipidemia rabbits, and cannot antagonize the formation of atherosclerosis
[0008] What are the reasons for these different results of anthocyanins? Due to the current research on the anti-atherosclerosis of anthocyanins, anthocyanin extraction mixtures from different plant sources are mostly used, and there are very few data obtained from the monomer components, which determines the uncertainty of the current research results
At the same time, most studies are limited to the observation of lipid-lowering efficacy, aortic atherosclerotic plaque thickness, area, and certain biochemical indicators, and seldom go deep into the expression and mechanism of cellular and subcellular active substances.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of anthocyanin and regulation for CHOP gene in preventing and treating atherosclerosis
  • Applications of anthocyanin and regulation for CHOP gene in preventing and treating atherosclerosis
  • Applications of anthocyanin and regulation for CHOP gene in preventing and treating atherosclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Example 1: Effect of cyanidin-3,5-diglucoside on mouse RAW264.7 macrophages

[0030] 1 Experimental materials

[0031] 1.1 Experimental drugs

[0032] Cyanidin-3,5-diglucoside: a monomer of anthocyanin, purchased from Sigma Company in the United States, catalog number 74397, English name Cyanin chloride, also known as Cyanidin-3,5-di-O- glucoside, formula C 27 h 31 ClO 16 , the molecular weight is 646.98, and the chemical structure is shown below.

[0033]

[0034] 1.2 Experimental objects

[0035] Mouse RAW264.7 macrophages: mouse mononuclear macrophage leukemia cells, derived from the Cell Bank of the Type Culture Collection Committee of the Chinese Academy of Sciences in Shanghai, catalog number TCM13.

[0036] 1.3 Reagents

[0037] 3-(4,5-dimethylthiazole-2)-2,5-diphenyltetrazolium bromide (thiazolium blue, MTT) was purchased from American Fluka Company; dimethylsulfoxide (DMSO) was purchased from American Sigma Company; RPMI-1640 medium and fetal bovine ...

Embodiment 2

[0057] Example 2: The improvement effect of cyanidin-3,5-diglucoside on the injury of mouse RAW264.7 macrophage cell line induced by ox-LDL

[0058] 1 Experimental materials

[0059] 1.1 Experimental drugs

[0060] cyanidin-3,5-diglucoside: same as specific example 1.

[0061] 1.2 Experimental objects

[0062] Mouse RAW264.7 macrophages: same as in Example 1.

[0063] 1.3 Reagents

[0064] ox-LDL was purchased from Beijing Concord Biochemical Laboratory; MTT was purchased from Fluka Company of the United States; DMSO was purchased from Sigma Company of the United States; RPMI-1640 medium and fetal bovine serum were purchased from Gibco Company of the United States; trypsin was purchased from Wuhan Life Science Technology Company.

[0065] 1.4 Instruments

[0066] With specific embodiment 1.

[0067] 2 Experimental method:

[0068] 2.1 Culture of RAW264.7 cells

[0069] With specific embodiment 1.

[0070] 2.2 Grouping and administration method

[0071] The cyanidin-3...

Embodiment 3

[0083] Example 3: Effect of cyanidin-3,5-diglucoside on the gene expression profile of ox-LDL-treated mouse RAW264.7 macrophage cell line

[0084] 1 Experimental materials

[0085] 1.1 Experimental drugs

[0086] cyanidin-3,5-diglucoside: same as specific example 1.

[0087] 1.2 Experimental objects

[0088] Mouse RAW264.7 macrophages: same as in Example 1.

[0089] 1.3 Reagents

[0090] ox-LDL was purchased from Beijing Concord Biochemical Laboratory; MTT was purchased from Fluka Company of the United States; DMSO was purchased from Sigma Company of the United States; RPMI-1640 medium and fetal bovine serum were purchased from Gibco Company of the United States; trypsin was purchased from Wuhan Life Science Technology Company; TRIZOL The reagents were purchased from Shanghai Bioengineering Company; the RNA purification kit (RNeasy Total RNA Isolation kit) was from QIAGEN, USA; the AffymetrixMouse U430 2.0 gene expression profile chip was from Affymetrix, USA; the reverse ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the use of anthocyanin in medicines for treating atherosclerosis and the application for preventing and treating atherosclerosis with regulation and control of CHOP gene, and relates to the improvement effect of anthocyanin monomer cyanidin-3, 5-diglucoside on macrophage injuries caused by oxidized low density lipoprotein, and discusses the mechanism of action thereof. In the invention, mouse macrophage cell line RAW264.7 is tested, and the effect of cyanidin-3, 5-diglucoside on activity of RAW264.7 macrophage processed by the oxidized low density lipoprotein is determined based on MTT method, the total RNA of cells is extracted, Affymetrix Mouse U4302.0 gene expression profile chip is applied to carry out marking hybridization experiments, differential gene analysis is carried out for the scanning results of Affyemtrix gene chip with MTT method, and the differential genes are screened, and further real-time quantitative PRC method is utilized to further validate the expressed differential gene, The validation results verify that the cyanidin-3, 5-diglucoside can regulate CHOP gene expression down, and has obvious protective action on macrophages injured by oxidized low density lipoprotein.

Description

technical field [0001] The present invention relates to the technical field of medicine, in particular to the use of an anthocyanin monomer, cyanidin-3,5-diglucoside in the preparation of medicines and health foods for the prevention or treatment of atherosclerosis; C / EBP homologous protein) gene regulation in the prevention and treatment of atherosclerosis. Background technique [0002] The prevalence of atherosclerosis has been increasing for more than 100 years. Worldwide, the number of deaths caused by atherosclerosis and thrombosis accounts for 52% of all deaths, far exceeding the second cause of death, tumors. (24%), becoming the veritable No. 1 killer of death. Atherosclerosis is a systemic disease that can lead to dysfunction of major organs in the body, such as the heart, brain, kidney, and even limbs, seriously affecting the quality of life of patients, and also bringing heavy burdens to families and the social economy. Therefore, it is very necessary to find hig...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P9/10
Inventor 毕勇毅欧阳静萍王保华张叶敏沈同李阳
Owner WUHAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com